Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis (NCT07220577)

🧪 Interventions in This Study

• GIA632 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (28 Sites)

Showing the first 25 of 28 sites.

• Ctr for Dermatology Clinical Res — Fremont, California
• Aesthetics Skin Care Dermatologic Surgery — Rockville, Maryland
• Care Access Hoboken — Hoboken, New Jersey
• Novartis Investigative Site — Pleven,
• Novartis Investigative Site — Sofia,
• Novartis Investigative Site — Sofia,
• Novartis Investigative Site — Toronto, Ontario
• Novartis Investigative Site — Québec, Quebec
• Novartis Investigative Site — Ostrava, Poruba
• Novartis Investigative Site — Brno,
• Novartis Investigative Site — Prague,
• Novartis Investigative Site — Antony,
• Novartis Investigative Site — Dijon,
• Novartis Investigative Site — Martigues,
• Novartis Investigative Site — Nice,
• Novartis Investigative Site — Berlin,
• Novartis Investigative Site — Hamburg,
• Novartis Investigative Site — Mainz,
• Novartis Investigative Site — Ipoh, Perak
• Novartis Investigative Site — George Town, Pulau Pinang
• Novartis Investigative Site — Kota Kinabalu, Sabah
• Novartis Investigative Site — Kuala Lumpur,
• Novartis Investigative Site — Gdansk,
• Novartis Investigative Site — Torun,
• Novartis Investigative Site — Warsaw,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Atopic Dermatitis

• A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
• ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
• A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
• Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
• A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
• A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California

Explore by condition: All Atopic Dermatitis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.